melatonin has been researched along with s20098 in 162 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 27 (16.67) | 18.2507 |
| 2000's | 46 (28.40) | 29.6817 |
| 2010's | 80 (49.38) | 24.3611 |
| 2020's | 9 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Andrieux, J; Guardiola-Lemaitre, B; Howell, HE; Lesieur, D; Morgan, PJ; Pfeiffer, B; Renard, P; Yous, S | 1 |
| Andrieux, J; Brémont, B; Delagrange, P; Langlois, M; Mathé-Allainmat, M; Poncet, A; Renard, P; Serraz, I; Shen, S; Sicsic, S | 1 |
| Caignard, DH; Delagrange, P; Depreux, P; Guardiola, B; Howell, HE; Lesieur, D; Mansour, HA; Morgan, P; Pfeiffer, B; Renard, P | 1 |
| Andrieux, J; Brémont, B; Langlois, M; Mathé-Allainmat, M; Poncet, A; Serraz, I; Shen, S; Sicsic, S | 1 |
| Balsamini, C; Bordi, F; Diamantini, G; Fraschini, F; Lucini, V; Mor, M; Nonno, R; Plazzi, PV; Rivara, S; Silva, C; Spadoni, G; Stankov, BM; Tarzia, G | 1 |
| Andrieux, J; Delagrange, P; Jellimann, C; Langlois, M; Mathé-Allainmat, M; Renard, P | 1 |
| Andrieux, J; Bennejean, C; Boutin, JA; Delagrange, P; Jellimann, C; Kloubert, S; Langlois, M; Mathé-Allainmat, M; Nicolas, JP | 1 |
| Audinot, V; Bennejean, C; Bonnaud, A; Boutin, JA; Chavatte, P; Delagrange, P; Descamps-François, C; Lesieur, D; Renard, P; Yous, S | 1 |
| Cussac, D; Dekeyne, A; Gobert, A; Lejeune, F; Millan, MJ; Newman-Tancredi, A; Pasteau, V; Rivet, JM | 1 |
| Amossé, C; Audinot, V; Bonnaud, A; Boutin, JA; Delagrange, P; Dromaint, S; Galizzi, JP; Guillaumet, G; Lahaye-Brasseur, C; Le Gall, A; Lefoulon, F; Lesieur, D; Mailliet, F; Malpaux, B; Nagel, N; Renard, P; Rodriguez, M | 1 |
| Audinot, V; Bennejean, C; Berthelot, P; Boutin, JA; Caignard, DH; Delagrange, P; Ettaoussi, M; Lesieur, D; Pérès, B; Poissonnier-Durieux, S; Renard, P; Yous, S | 1 |
| Audinot, V; Bennejean, C; Berthelot, P; Boutin, JA; Caignard, DH; Chavatte, P; Coumailleau, S; Delagrange, P; Descamps-François, C; Mésangeau, C; Pérès, B; Renard, P; Yous, S | 1 |
| Chandrasena, G; Doller, D; Jiang, Y; Keim, H; Li, G; Poda, SB; Ren, Y; Topiol, SW; Zhou, H | 1 |
| Caignard, DH; Delagrange, P; Langlois, M; Lefas-Le Gall, M; Mathé-Allainmat, M; Morellato, L; Renard, P | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Alonso-Gil, S; Caignard, DH; de la Fuente Revenga, M; Fernández-Sáez, N; Herrera-Arozamena, C; Morales-García, JA; Pérez-Castillo, A; Rivara, S; Rodríguez-Franco, MI | 1 |
| Berthelot, P; Boutin, JA; Caignard, DH; Delagrange, P; Duroux, R; Ettaoussi, M; Landagaray, E; Melnyk, P; Yous, S | 1 |
| Berthelot, P; Boutin, JA; Caignard, DH; Delagrange, P; Ettaoussi, M; Landagaray, E; Melnyk, P; Rami, M; Yous, S | 1 |
| Armstrong, SM; Brown, M; Delagrange, P; Guardiola-Lemaitre, B; Redman, JR | 1 |
| Borbély, AA; Jaggi, K; Tobler, I | 1 |
| Armstrong, SM; Guardiola-Lemaitre, B; McNulty, OM; Redman, JR | 1 |
| Carlberg, C; Jagher, B; Missbach, M; Nayeri, S; Sigg, I; Wiesenberg, I | 1 |
| Delagrange, P; Guardiola-Lemaitre, B; Mocaer, E; Renard, P; Rusak, B; Ying, SW | 1 |
| Bentivoglio, M; Grassi-Zucconi, G; Kristensson, K; Mocaer, E; Semprevivo, M | 1 |
| Guardiola-Lemaitre, B; Martinet, L; Mocaer, E | 1 |
| Cajochen, C; Graw, P; Kräuchi, K; Möri, D; Wirz-Justice, A | 2 |
| Niles, LP; Tenn, CC | 1 |
| Defrance, R; Mocaer, E; Olivares, E; Turek, FW; Van Reeth, O; Zee, PC; Zhang, Y | 1 |
| Francis, AJ; Redman, JR | 1 |
| Mocaër, E; Rusak, B; Ying, SW | 1 |
| Granjon, L; Mocaer, E; Olivares, E; Turek, FW; Van Reeth, O | 1 |
| Delagrange, P; Guardiola-Lemaitre, B; Guerrero, HY; Masson-Pévet, M; Mocaer, E; Pévet, P; Recio, J | 1 |
| Balster, RL; Dance, ME; Wiley, JL | 1 |
| Calvo, JR; Garcia-Mauriño, S; Goberna, R; Gonzalez-Haba, MG; Guerrero, JM | 1 |
| Bucher, B; Gauer, F; Masson-Pévet, M; Pévet, P | 1 |
| Flanders, S; Lew, MJ | 1 |
| Kirsch, R; Malan, A; Mocaer, E; Pevet, P; Pitrosky, B | 1 |
| Boursier-Neyret, C; Bromet, N; Bru, L; Jeanniot, JP; Lelièvre, E; Simonin, G; Walther, B | 1 |
| Barrett, P; Canning, SJ; Conway, S; Delagrange, P; Drew, JE; Howell, HE; Lesieur, D; Morgan, PJ; Mowat, ES | 1 |
| Hu, DN; Roberts, JE; Wiechmann, AF | 1 |
| Chu, YS; Pan, JT; Shieh, KR; Yuan, ZF | 1 |
| Chignell, CF; Hu, DN; Martinez, L; Roberts, JE | 1 |
| Mocaer, E; Turek, FW; Van Reeth, O; Weibel, L | 1 |
| Calvo, JR; García-Mauriño, S; Guerrero, JM; Pozo, D | 1 |
| Jantos, H; Monti, D; Monti, JM | 1 |
| Maccari, S; Mocaer, E; Olivares, E; Turek, FW; Van Reeth, O; Weibel, L | 1 |
| Barrett, P; Conway, S; Delagrange, P; Drew, JE; Morgan, PJ; Mowat, ES | 1 |
| Koolhaas, JM; Mocaër, E; Strubbe, JH; Tuma, J | 1 |
| D'haenen, H; Hale, A; Lôo, H | 1 |
| Calvo, JR; Carrillo-Vico, A; García-Mauriño, S; Guerrero, JM | 1 |
| Chagraoui, A; Filloux, T; Mocaër, E; Protais, P | 1 |
| Brocco, M; Dekeyne, A; Gobert, A; Millan, MJ | 1 |
| Guerrero, JM; Leon-Blanco, MM; Pozo, D; Reiter, RJ | 1 |
| Gillette, MU; Turek, FW | 1 |
| Hamon, M; Le Bihan, C; Loiseau, F; Thiébot, MH | 2 |
| Barden, N; Labbé, M; Mocaër, E; Rochford, J; Shink, E; Vacher, R | 1 |
| Copinschi, G; L'hermite-Balériaux, M; Leproult, R; Van Cauter, E; Van Onderbergen, A | 1 |
| Boyer, PA; de Bodinat, C; Delalleau, B; Mocaër, E | 1 |
| Gruca, P; Litwa, E; Mocaër, E; Papp, M | 1 |
| Wirz-Justice, A | 1 |
| Fuchs, E; Schmelting, B; Simon, M | 1 |
| Bertaina-Anglade, V; Boyer, PA; la Rochelle, CD; Mocaër, E | 1 |
| Steinhilber, D | 1 |
| Chalivoix, S; Delagrange, P; Fuchs, E; Gabriel, C; Legros, C; Malpaux, B; Mocaer, E | 1 |
| Ghosh, A; Hellewell, JS | 1 |
| Cardinali, DP; Hardeland, R; Pandi-Perumal, SR; Poeggeler, B; Srinivasan, V; Trakht, I | 1 |
| Gressens, P; Husson, I; Mocaer, E; Sarkozy, G; Schwendimann, L; Spedding, M; Vamecq, J | 1 |
| Arranz, B; San, L | 1 |
| Cardinali, DP; Hardeland, R; Pandi-Perumal, SR; Poeggeler, B; Spence, DW; Srinivasan, V; Trakht, I | 2 |
| Arendt, J; Rajaratnam, SM | 1 |
| Cardinali, DP; Hardeland, R; Pandi-Perumal, SR; Poeggeler, B; Spence, DW; Srinivasan, V; Trahkt, I | 1 |
| Cespuglio, R; Delagrange, P; Descamps, A; Millan, M; Millan, MJ; Rousset, C; Spedding, M | 1 |
| Brown, GM; Cardinali, DP; Moscovitch, A; Pandi-Perumal, SR; Spence, DW; Srinivasan, V | 1 |
| Emsley, R; Goodwin, GM; Rembry, S; Rouillon, F | 1 |
| Kálmán, J; Kálmán, S | 1 |
| Owen, RT | 1 |
| Calabrese, F; Gabriel, C; Mocaer, E; Molteni, R; Pisoni, S; Racagni, G; Riva, MA | 1 |
| Dawson, D; Ferguson, SA; Rajaratnam, SM | 1 |
| Guilleminault, C; Lemoine, P; Quera-Salva, MA | 1 |
| Bonanno, G; Bonifacino, T; Gabriel-Gracia, C; Grilli, M; Mallei, A; Milanese, M; Mocaer, E; Musazzi, L; Popoli, M; Racagni, G; Tardito, D | 1 |
| de Bodinat, C; Guardiola-Lemaitre, B; Millan, MJ; Mocaër, E; Muñoz, C; Renard, P | 1 |
| AlAhmed, S; Herbert, J | 1 |
| Brown, GM; Cardinali, DP; Pandi-Perumal, SR; Singh, J; Spence, DW; Srinivasan, V | 1 |
| Acciavatti, T; Cavuto, M; Conti, C; Conti, P; De Berardis, D; Di Giannantonio, M; Di Iorio, G; Janiri, L; Martinotti, G; Moschetta, FS; Olivieri, L; Serroni, N | 1 |
| Somoskovi, C; Sumegi, A | 1 |
| Bagdy, G; Gonda, X; Molnar, E; Rihmer, Z | 1 |
| Bertaina-Anglade, V; Drieu-La-Rochelle, C; Mocaër, E; Seguin, L | 1 |
| Brown, GM; Brzezinski, A; Cardinali, DP; Pandi-Perumal, SR; Spence, DW; Srinivasan, V | 1 |
| Alvarez, JC; Barbot, F; Guilleminault, C; Hartley, S; Lofaso, F; Quera Salva, MA | 1 |
| Hickie, IB; Rogers, NL | 1 |
| Guilleminault, C; Hajak, G; Keufer-Le Gall, S; Laredo, J; Montplaisir, J; Philip, P; Quera-Salva, MA | 1 |
| Arushanian, ÉB | 1 |
| Brown, GM; Brzezinski, A; Cardinali, DP; Srinivasan, V | 1 |
| Chancellor, D | 1 |
| Cranston, I; Dekeyne, A; Gabriel, C; Irons, JA; Millan, MJ; Mocaër, E; Norman, TR | 1 |
| Kennedy, SH; Majadas, S; Montejo, A; Rizvi, SJ | 1 |
| Dobrek, Ł; Thor, PJ | 1 |
| Bellantuono, C; Catena-Dell'Osso, M; Marazziti, D; Rotella, F | 1 |
| Hardeland, R; Poeggeler, B | 1 |
| Aguiar, CC; Almeida, AB; Araújo, PV; Chaves, EM; de Sousa, FC; do Vale, OC; Macêdo, DS; Vasconcelos, GS; Vasconcelos, SM; Viana, GS | 1 |
| Blier, P; Chenu, F; El Mansari, M | 1 |
| Brzezinski, A; De Berardis, D; Shillcutt, SD; Srinivasan, V | 1 |
| Acuña-Castroviejo, D; Lauterbach, EC; Othman, Z; Srinivasan, V; Zakaria, R | 1 |
| Bergua, A; Fonseca, B; Martínez-Águila, A; Pintor, J | 1 |
| Llorca, PM | 1 |
| Hamon, M; Lanfumey, L; Mongeau, R | 1 |
| Norman, TR | 1 |
| Prokop'eva, ML; Sobennikov, VS | 1 |
| Kennedy, SH; Picarel-Blanchot, F; Stein, DJ | 1 |
| De Berardis, D; di Giannantonio, M; Fornaro, M; Iasevoli, F; Marini, S; Martinotti, G; Perna, G; Quera-Salva, MA; Srinivasan, V; Tomasetti, C; Valchera, A | 1 |
| Corbach-Söhle, S; Flügge, G; Fuchs, E; Kohlhause, S; Schlumbohm, C; Schmelting, B | 1 |
| Delmonte, D; Smeraldi, E | 1 |
| Bhutada, PS; Patel, FR; Vimala, PV | 1 |
| Bothorel, B; Castanho, A; Mocaër, E; Pévet, P; Seguin, L | 1 |
| Chiodo, D; Davies, SJ; Guaiana, G; Gupta, S; Haederle, K; Koesters, M | 1 |
| Du, Q; Jiang, X; Song, L; Wang, L | 1 |
| Cullen, T; Findlay, G; Gardani, M; O'Neill, B; Whyte, T | 1 |
| Gorbenko, MV; Popov, SS; Popova, TN; Shul'gin, KK | 1 |
| Amore, M; Carbini, G; Mercolini, L; Quarta, AL; Raggi, MA; Saracino, MA; Volterra, V | 1 |
| Amore, M; Benassi, F; Cocito, L; Cordano, C; Emberti Gialloreti, L; Guida, S; Mattei, C; Pardini, M; Primavera, A; Sassos, D; Serrati, C | 1 |
| Nance, M; Pannell, J; Thorpe, M | 1 |
| Turbina, LG | 1 |
| Gupta, S; Sharma, B | 1 |
| Chel'naia, NA; Iasnetsov, VV; Ivanov, IuV; Karsanova, SK; Motin, VG | 1 |
| Frydman-Marom, A; Laudon, M | 1 |
| Hardeland, R | 1 |
| Ivanchuk, ÉG; Rostovshchikov, VV; Tarakanova, EA | 1 |
| Gatto, V; Pescosolido, N; Rusciano, D; Stefanucci, A | 1 |
| Baroncini, M; Benleulmi-Chaachoua, A; Chen, P; Daulat, AM; Delagrange, P; Gbahou, F; Guillaume, JL; Jockers, R; Kalbasi Anaraki, D; Kamal, M; Luka, M; Mannoury la Cour, C; Millan, MJ; Prevot, V | 1 |
| Karsanova, SK; Yasnetsov, VV | 1 |
| Noori, HR; Spanagel, R; Vengeliene, V | 1 |
| Petrova, MM; Piliugina, MS; Savchenko, AA; Shimohina, NY | 1 |
| Bogdanovskaya, M; Cowen, PJ; Harmer, CJ; Pringle, A; Waskett, P; Zacharia, S | 1 |
| Abreu, T; Bragança, M | 1 |
| Forneris, CA; Gartlehner, G; Gaynes, BN; Greenblatt, A; Hofmann, J; Kaminski-Hartenthaler, A; Lux, LJ; Morgan, LC; Nussbaumer, B; Sonis, JH; Van Noord, MG; Winkler, D; Wipplinger, J | 1 |
| Copoglu, US; Dokuyucu, R; Erbas, O; Inanir, A; Inanir, S; Kokacya, H | 1 |
| Amore, M; Benassi, F; Callegari, I; Cocito, L; Emberti Gialloreti, L; Grafman, J; Krueger, F; Massucco, D; Mattei, C; Nobili, F; Pardini, M; Sassos, D; Scialò, C; Serrati, C; Yaldizli, Ö | 1 |
| Auer, S; Bergamini, G; Cathomas, F; Gabriel, C; Patterson, M; Pryce, CR; Seifritz, E; Sigrist, H | 1 |
| Blum, J; Suenderhauf, C; Vogel, M; Walter, A; Zormann, A | 1 |
| Deuschle, M; Fischer, EC; Zapp, AA | 1 |
| Chan, JYH; Hsu, CN; Lee, CT; Lin, YJ; Tain, YL | 1 |
| Bouzinova, EV; Christiansen, SL; Højgaard, K; Wiborg, O | 1 |
| Lim, DY; Ng, QX; Soh, AYS; Yeo, WS | 1 |
| Atanasova, D; Atanasova, M; Ilieva, K; Kortenska, L; Tchekalarova, J | 1 |
| Batyuk, A; Brehm, W; Cherezov, V; Gati, C; Grandner, JM; Grant, TD; Han, GW; Huang, XP; Ishchenko, A; Johansson, LC; Katritch, V; Liu, W; Madsen, C; McCorvy, JD; Michaelian, N; Olsen, RHJ; Patel, N; Roth, BL; Shiriaeva, A; Slocum, ST; Stauch, B; Stevens, RC; Tribo, AR; Weierstall, U; White, TA; Yous, S; Zhu, L | 1 |
| Aygun, H; Gul, SS | 1 |
| Forneris, CA; Gartlehner, G; Gaynes, BN; Greenblatt, A; Kaminski-Hartenthaler, A; Lux, LJ; Morgan, LC; Nussbaumer-Streit, B; Van Noord, MG; Winkler, D; Wipplinger, J | 1 |
| Qi, ZX; Wei, ZX; Zhou, N | 1 |
| Chumboatong, W; Govitrapong, P; Khamchai, S; Tocharus, C; Tocharus, J | 1 |
| Aydın, A; Gürbüz, MA; Halıcı, Z; Karaman, A; Köse, A; Köse, D; Toktay, E; Ugan, RA | 1 |
| Amato, R; Bagnoli, P; Cammalleri, M; Corsaro, R; Dal Monte, M; Pezzino, S; Rusciano, D | 1 |
| Carpenter, JS; Fogel, S; Hickie, IB; Louati, K; Porteous, M; Ray, L; Robillard, R | 1 |
| Anhê, GF; Bordin, S; de Souza, DN; Hecht, FB; Murata, GM; Pioli, MR; Santos-Silva, JC; Teixeira, CJ; Veronesi, VB; Vicente, JM | 1 |
| Bomsel, M; Cecon, E; Dam, J; Ghigna, MR; Izabelle, C; Jockers, R; Klonjkowski, B; Poder, SL; Real, F; Tu, L; Zhu, A | 1 |
| Du, ZW; Li, LD; Nan, S; Naveed, M; Sheng, G; Zhang, J; Zhou, QG; Zhou, YP; Zhu, MY | 1 |
| Lungkaphin, A; Pengrattanachot, N; Phengpol, N; Promsan, S; Sutthasupha, P; Thongnak, L | 1 |
| Algieri, F; Diez-Echave, P; Duarte, J; Gálvez, J; García, F; Garrido-Mesa, J; Hidalgo-García, L; Morón, R; Rodríguez-Cabezas, ME; Rodríguez-Nogales, A; Romero, M; Ruiz-Malagón, AJ; Sánchez, M; Toral, M; Vezza, T | 1 |
41 review(s) available for melatonin and s20098
| Article | Year |
|---|---|
Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists.
Topics: Acetamides; Antioxidants; Humans; Hypothalamus; Indenes; Indoles; Melatonin; Receptors, Melatonin; Sleep Disorders, Circadian Rhythm | 2004 |
[Development of a new antidepressant : agomelatine].
Topics: Acetamides; Animals; Circadian Rhythm; Depressive Disorder; Disease Models, Animal; Humans; Hypnotics and Sedatives; Melatonin; Receptor, Serotonin, 5-HT2C | 2005 |
Biological rhythm disturbances in mood disorders.
Topics: Acetamides; Antidepressive Agents; Biological Clocks; Circadian Rhythm; Clinical Trials as Topic; Depressive Disorder; Drugs, Investigational; Humans; Melatonin; Phototherapy; Sleep Deprivation | 2006 |
Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system.
Topics: Acetamides; Animals; Antidepressive Agents; Biological Clocks; Brain; Depressive Disorder, Major; Disease Models, Animal; Drug Evaluation, Preclinical; Drugs, Investigational; Humans; Melatonin; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Antagonists; Tupaiidae | 2006 |
[Melatonin, melatonin receptor agonists and tryptophan as sleep aids].
Topics: Acetamides; Animals; Antioxidants; Humans; Hypnotics and Sedatives; Indenes; Melatonin; Receptors, Melatonin; Sleep Wake Disorders; Tryptophan | 2007 |
A review of the efficacy and tolerability of agomelatine in the treatment of major depression.
Topics: Acetamides; Animals; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Melatonin | 2007 |
Melatonergic drugs in clinical practice.
Topics: Acetamides; Animals; Antidepressive Agents; Biological Clocks; Humans; Hypnotics and Sedatives; Indenes; Melatonin; Receptors, Melatonin; Sleep Initiation and Maintenance Disorders | 2008 |
Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
Topics: Acetamides; Animals; Circadian Rhythm; Depressive Disorder, Major; Dopamine; Frontal Lobe; Humans; Hypnotics and Sedatives; Melatonin; Norepinephrine; Randomized Controlled Trials as Topic; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists | 2008 |
The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives.
Topics: Acetamides; Affect; Antidepressive Agents; Brain; Depressive Disorder, Major; Humans; Indenes; Melatonin; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Sleep; Sleep Initiation and Maintenance Disorders | 2009 |
Pathophysiology of depression: role of sleep and the melatonergic system.
Topics: Acetamides; Antidepressive Agents; Circadian Rhythm; Depression; Humans; Melatonin; Prevalence; Receptors, Melatonin; Sleep; Sleep Stages; Sleep Wake Disorders; Suprachiasmatic Nucleus; Wakefulness | 2009 |
Melatonin and melatonergic drugs on sleep: possible mechanisms of action.
Topics: Acetamides; Aging; Animals; Antidepressive Agents; Circadian Rhythm; Depressive Disorder; Humans; Hypnotics and Sedatives; Indenes; Melatonin; Receptors, Melatonin; Signal Transduction; Sleep; Sleep Initiation and Maintenance Disorders; Suprachiasmatic Nucleus | 2009 |
Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine.
Topics: Acetamides; Animals; Brain; Chronobiology Disorders; Circadian Rhythm; Depressive Disorder, Major; Humans; Hypnotics and Sedatives; Melatonin; Sleep; Sleep Wake Disorders | 2009 |
[Depression as chronobiological illness].
Topics: Acetamides; Affect; Biological Clocks; Chronotherapy; Circadian Rhythm; Depression; Depressive Disorder, Major; Humans; Hypnotics and Sedatives; Melatonin; Mood Disorders; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Sleep; Sleep Deprivation; Sleep Wake Disorders; Suprachiasmatic Nucleus | 2009 |
Agomelatine: a novel pharmacological approach to treating depression.
Topics: Acetamides; Animals; Antidepressive Agents; Anxiety; Depressive Disorder, Major; Drug Interactions; Humans; Melatonin; Secondary Prevention; Sleep Wake Disorders; Substance Withdrawal Syndrome | 2009 |
Melatonin agonists and insomnia.
Topics: Acetamides; Animals; Benzofurans; Circadian Rhythm; Cyclopropanes; Humans; Hypnotics and Sedatives; Indenes; Melatonin; Sleep Initiation and Maintenance Disorders | 2010 |
Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients.
Topics: Acetamides; Animals; Antidepressive Agents; Depressive Disorder, Major; Humans; Melatonin; Randomized Controlled Trials as Topic; Sleep Disorders, Circadian Rhythm; Sleep Wake Disorders | 2010 |
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.
Topics: Acetamides; Animals; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Drug Design; Drug Discovery; Humans; Melatonin; Serotonin 5-HT2 Receptor Antagonists | 2010 |
Jet lag, circadian rhythm sleep disturbances, and depression: the role of melatonin and its analogs.
Topics: Acetamides; Benzofurans; Central Nervous System Depressants; Cyclopropanes; Depressive Disorder; Humans; Indenes; Jet Lag Syndrome; Melatonin; Sleep Disorders, Circadian Rhythm | 2010 |
The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.
Topics: Acetamides; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Melatonin; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2 | 2011 |
[Lights off? Neurobiological and pharmacological aspects of the melatonergic-serotonergic synergism].
Topics: Acetamides; Antidepressive Agents; Circadian Rhythm; Depression; Depressive Disorder; Drug Synergism; Humans; Hypnotics and Sedatives; Melatonin; Meta-Analysis as Topic; Receptors, Melatonin; Serotonin; Sleep Disorders, Circadian Rhythm | 2010 |
[Etiopathology and therapy of seasonal affective disorder].
Topics: Acetamides; Antidepressive Agents; Circadian Rhythm; Cognitive Behavioral Therapy; Humans; Hypnotics and Sedatives; Melatonin; Neurotransmitter Agents; Phototherapy; Physical Therapy Modalities; Randomized Controlled Trials as Topic; Seasonal Affective Disorder; Selective Serotonin Reuptake Inhibitors; Vitamin D | 2010 |
Melatonin agonists in primary insomnia and depression-associated insomnia: are they superior to sedative-hypnotics?
Topics: Acetamides; Animals; Benzodiazepines; Benzofurans; Clinical Trials as Topic; Cyclopropanes; Depressive Disorder; Humans; Hypnotics and Sedatives; Indenes; Indoles; Melatonin; Sleep Initiation and Maintenance Disorders | 2011 |
Circadian rhythms, melatonin and depression.
Topics: Acetamides; Animals; Antidepressive Agents; Biological Clocks; Chronobiology Disorders; Depressive Disorder, Major; Humans; Melatonin; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists | 2011 |
Novel melatonin-based therapies: potential advances in the treatment of major depression.
Topics: Acetamides; Antidepressive Agents; Chronobiology Disorders; Circadian Rhythm; Depressive Disorder, Major; Humans; Melatonin; Sleep | 2011 |
[Melatoninergic antidepressant valdoxan].
Topics: Acetamides; Antidepressive Agents; Circadian Rhythm; Depressive Disorder; Humans; Melatonin; Pineal Gland; Receptors, Melatonin; Receptors, Serotonin; Serotonin; Serotonin Antagonists; Sleep | 2011 |
Melatonin and its analogs in insomnia and depression.
Topics: Acetamides; Animals; Depression; Humans; Hypnotics and Sedatives; Indenes; Melatonin; Mice; Sleep Initiation and Maintenance Disorders | 2012 |
The effects of agomelatine on sexual function in depressed patients and healthy volunteers.
Topics: Acetamides; Animals; Antidepressive Agents; Depression; Humans; Melatonin; Selective Serotonin Reuptake Inhibitors; Sexual Behavior; Sexual Dysfunctions, Psychological; Treatment Outcome | 2011 |
Emerging targets for the pharmacological treatment of depression: focus on melatonergic system.
Topics: Acetamides; Antidepressive Agents; Circadian Clocks; Depression; Humans; Indenes; Melatonin; Receptors, Melatonin | 2012 |
Melatonin and synthetic melatonergic agonists: actions and metabolism in the central nervous system.
Topics: Acetamides; Animals; Antidepressive Agents; Central Nervous System; Humans; Indenes; Melatonin; Receptors, Melatonin; Sleep | 2012 |
Role of melatonin in mood disorders and the antidepressant effects of agomelatine.
Topics: Acetamides; Animals; Antidepressive Agents; Humans; Melatonin; Mood Disorders | 2012 |
Agomelatine in depressive disorders: its novel mechanisms of action.
Topics: Acetamides; Animals; Antidepressive Agents; Anxiety Disorders; Depressive Disorder; Disease Models, Animal; Humans; Melatonin; Receptors, Melatonin; Sleep Wake Disorders | 2012 |
[Early effects of antidepressants].
Topics: Acetamides; Affect; Antidepressive Agents; Controlled Clinical Trials as Topic; Depressive Disorder, Major; Humans; Hypnotics and Sedatives; Melatonin; Surveys and Questionnaires; Treatment Outcome | 2012 |
Biological rhythms and melatonin in mood disorders and their treatments.
Topics: Acetamides; Animals; Antidepressive Agents; Brain; Chronobiology Disorders; Circadian Rhythm; Humans; Hypnotics and Sedatives; Melatonin; Mood Disorders; Neuronal Plasticity | 2013 |
The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice.
Topics: Acetamides; Affect; Anxiety Disorders; Brain; Circadian Rhythm; Humans; Melatonin; Practice Patterns, Physicians' | 2013 |
Agomelatine in depression.
Topics: Acetamides; Animals; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Humans; Melatonin; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome | 2013 |
Agomelatine versus other antidepressive agents for major depression.
Topics: Acetamides; Adult; Antidepressive Agents; Depressive Disorder, Major; Humans; Melatonin; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors | 2013 |
Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders.
Topics: Acetamides; Animals; Benzofurans; Clinical Trials as Topic; Cyclopropanes; Humans; Hypnotics and Sedatives; Indenes; Melatonin; Neurodegenerative Diseases; Receptors, Melatonin; Sleep Wake Disorders | 2014 |
Melatonin and Synthetic Melatoninergic Agonists in Psychiatric and Age-associated Disorders: Successful and Unsuccessful Approaches.
Topics: Acetamides; Animals; Humans; Indoles; Melatonin; Memory Disorders; Mental Disorders; Pyrans; Receptors, Melatonin | 2016 |
The bipolarity of light and dark: A review on Bipolar Disorder and circadian cycles.
Topics: Acetamides; Affect; Antimanic Agents; Bipolar Disorder; Circadian Rhythm; Humans; Hypnotics and Sedatives; Light; Lithium Carbonate; Melatonin; Phototherapy; Sleep; Sleep Deprivation | 2015 |
Melatonin and agomelatine for preventing seasonal affective disorder.
Topics: Acetamides; Adult; Humans; Melatonin; Seasonal Affective Disorder | 2015 |
Melatonin and agomelatine for preventing seasonal affective disorder.
Topics: Acetamides; Adult; Antidepressive Agents; Humans; Melatonin; Placebos; Seasonal Affective Disorder | 2019 |
9 trial(s) available for melatonin and s20098
| Article | Year |
|---|---|
Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature.
Topics: Acetamides; Administration, Oral; Adult; Analysis of Variance; Body Temperature Regulation; Circadian Rhythm; Darkness; Double-Blind Method; Drug Administration Schedule; Heart Rate; Humans; Hypnotics and Sedatives; Light; Male; Melatonin; Periodicity; Placebos; Random Allocation; Skin Temperature | 1997 |
Melatonin and S-20098 increase REM sleep and wake-up propensity without modifying NREM sleep homeostasis.
Topics: Acetamides; Adult; Cross-Over Studies; Darkness; Double-Blind Method; Drug Administration Schedule; Homeostasis; Humans; Hypnotics and Sedatives; Light; Male; Melatonin; Placebos; Random Allocation; Regression Analysis; Sleep Stages; Sleep, REM; Wakefulness | 1997 |
Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study.
Topics: Acetamides; Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Melatonin; Paroxetine; Psychiatric Status Rating Scales; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Serotonin Antagonists; Treatment Outcome | 2002 |
Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men.
Topics: Acetamides; Aged; Body Temperature; Circadian Rhythm; Cross-Over Studies; Double-Blind Method; Growth Hormone; Hormones; Humans; Hydrocortisone; Jet Lag Syndrome; Male; Melatonin; Middle Aged; Monitoring, Physiologic; Prolactin; Sleep; Stimulation, Chemical; Thyrotropin | 2005 |
Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
Topics: Acetamides; Adolescent; Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypnotics and Sedatives; Kaplan-Meier Estimate; Male; Melatonin; Middle Aged; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Secondary Prevention; Serotonin 5-HT2 Receptor Antagonists; Substance Withdrawal Syndrome; Treatment Outcome | 2009 |
Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients.
Topics: Acetamides; Adult; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Male; Melatonin; Middle Aged; Polysomnography; Selective Serotonin Reuptake Inhibitors; Sleep Stages; Treatment Outcome; Wakefulness | 2011 |
Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression.
Topics: Acetamides; Adult; Antidepressive Agents; Anxiety; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Melatonin; Middle Aged; Treatment Outcome | 2013 |
Effect of CYP1A2 polymorphism on the pharmacokinetics of agomelatine in Chinese healthy male volunteers.
Topics: Acetamides; Adult; Alleles; Area Under Curve; Asian People; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A2; Genotype; Homozygote; Humans; Hypnotics and Sedatives; Male; Melatonin; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Tandem Mass Spectrometry; Young Adult | 2014 |
Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study.
Topics: Acetamides; Adult; Antidepressive Agents; Fatigue; Fatigue Syndrome, Chronic; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Melatonin; Pilot Projects; Psychiatric Status Rating Scales; Quality of Life; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome | 2014 |
112 other study(ies) available for melatonin and s20098
| Article | Year |
|---|---|
Novel naphthalenic ligands with high affinity for the melatonin receptor.
Topics: Animals; Melatonin; Naphthalenes; Radioligand Assay; Rats; Receptors, Melatonin; Receptors, Neurotransmitter | 1992 |
Design and synthesis of new naphthalenic derivatives as ligands for 2-[125I]iodomelatonin binding sites.
Topics: Animals; Binding Sites; Chickens; Drug Design; Iodine Radioisotopes; Ligands; Magnetic Resonance Spectroscopy; Melatonin; Naphthalenes; Radioligand Assay; Structure-Activity Relationship | 1995 |
Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands.
Topics: Acetamides; Animals; Cell Membrane; Colforsin; Cyclic AMP; Iodine Radioisotopes; Ligands; Melatonin; Molecular Structure; Pituitary Gland, Anterior; Receptors, Cell Surface; Receptors, Melatonin; Sheep; Structure-Activity Relationship | 1994 |
Three-dimensional quantitative structure-activity relationship of melatonin receptor ligands: a comparative molecular field analysis study.
Topics: Animals; Brain; Chickens; Ligands; Melatonin; Models, Molecular; Molecular Conformation; Molecular Structure; Polycyclic Compounds; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Receptors, Melatonin; Structure-Activity Relationship | 1997 |
Melatonin receptor ligands: synthesis of new melatonin derivatives and comprehensive comparative molecular field analysis (CoMFA) study.
Topics: Animals; Ligands; Melatonin; Models, Molecular; Molecular Conformation; Quail; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Receptors, Melatonin; Structure-Activity Relationship; Superior Colliculi | 1998 |
Melatonergic properties of the (+)- and (-)-enantiomers of N-(4-methoxy-2,3-dihydro-1H-phenalen-2-yl)amide derivatives.
Topics: Acetamides; Animals; Brain; Chickens; Chromatography, High Pressure Liquid; In Vitro Techniques; Ligands; Melatonin; Phenalenes; Polycyclic Compounds; Radioligand Assay; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Receptors, Melatonin; Skin; Stereoisomerism; Structure-Activity Relationship; Xenopus laevis | 1999 |
Synthesis of phenalene and acenaphthene derivatives as new conformationally restricted ligands for melatonin receptors.
Topics: Acenaphthenes; Animals; Binding, Competitive; Brain; Cell Line; Chickens; Female; Humans; In Vitro Techniques; Larva; Ligands; Male; Models, Molecular; Pigmentation; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Receptors, Melatonin; Skin; Stereoisomerism; Structure-Activity Relationship; Xenopus laevis | 2000 |
Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands.
Topics: Acetamides; Animals; Cell Line; Cricetinae; Dimerization; Drug Design; Humans; Ligands; Melatonin; Naphthalenes; Radioligand Assay; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Receptors, Melatonin; Structure-Activity Relationship | 2003 |
The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways.
Topics: Acetamides; Animals; Binding Sites; Corpus Striatum; Dopamine; Electrophysiology; Frontal Lobe; Male; Melatonin; Neurons; Norepinephrine; Nucleus Accumbens; Penile Erection; Prefrontal Cortex; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Adrenergic; Receptors, Dopamine; Receptors, Serotonin; Serotonin Antagonists; Synaptic Transmission; Tritium | 2003 |
New selective ligands of human cloned melatonin MT1 and MT2 receptors.
Topics: Animals; Cell Line; CHO Cells; Cloning, Molecular; Cricetinae; Dose-Response Relationship, Drug; Humans; Ligands; Melatonin; Protein Binding; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2 | 2003 |
Synthesis of 3-phenylnaphthalenic derivatives as new selective MT(2) melatoninergic ligands.
Topics: Acetamides; Animals; Binding Sites; Cell Line; CHO Cells; Cricetinae; Cricetulus; Drug Design; Furans; Humans; Indoles; Ligands; Melatonin; Naphthalenes; Radioligand Assay; Receptor, Melatonin, MT2; Structure-Activity Relationship | 2008 |
Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT(1) melatoninergic ligands.
Topics: Acetamides; Animals; Binding Sites; Binding, Competitive; Cell Line; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Drug Design; Melatonin; Protein Binding; Quantitative Structure-Activity Relationship; Receptor, Melatonin, MT1; Receptors, Melatonin | 2010 |
Design and synthesis of 4-arylpiperidinyl amide and N-arylpiperdin-3-yl-cyclopropane carboxamide derivatives as novel melatonin receptor ligands.
Topics: Amides; Animals; Cyclopropanes; Drug Design; Humans; Ligands; Microsomes; Piperidines; Rats; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Structure-Activity Relationship | 2011 |
Synthesis of new N-(arylcyclopropyl)acetamides and N-(arylvinyl)acetamides as conformationally-restricted ligands for melatonin receptors.
Topics: Acetamides; Animals; Chickens; Cyclopropanes; Humans; Ligands; Molecular Conformation; Molecular Structure; Protein Binding; Receptors, Melatonin; Recombinant Proteins; Vinyl Compounds | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Novel N-Acetyl Bioisosteres of Melatonin: Melatonergic Receptor Pharmacology, Physicochemical Studies, and Phenotypic Assessment of Their Neurogenic Potential.
Topics: Animals; Cells, Cultured; CHO Cells; Cricetulus; Humans; Male; Melatonin; Models, Molecular; Neural Stem Cells; Neurogenesis; Oxadiazoles; Rats; Rats, Wistar; Receptors, Melatonin; Thiadiazoles | 2015 |
Melatonergic ligands: Design, synthesis and pharmacological evaluation of novel series of naphthofuranic derivatives.
Topics: Animals; CHO Cells; Cricetulus; Drug Design; Furans; HEK293 Cells; Humans; Ligands; Melatonin; Naphthalenes; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2 | 2016 |
New quinolinic derivatives as melatonergic ligands: Synthesis and pharmacological evaluation.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Drug Design; HEK293 Cells; Humans; Indoles; Ligands; Melatonin; Quinolines; Structure-Activity Relationship | 2017 |
Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms.
Topics: Acetamides; Animals; Circadian Rhythm; Dose-Response Relationship, Drug; Hypnotics and Sedatives; Male; Melatonin; Motor Activity; Rats; Rats, Wistar | 1995 |
Effects of melatonin and the melatonin receptor agonist S-20098 on the vigilance states, EEG spectra, and cortical temperature in the rat.
Topics: Acetamides; Animals; Arousal; Body Temperature; Cerebral Cortex; Electroencephalography; Male; Melatonin; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; Receptors, Melatonin | 1994 |
Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS).
Topics: Acetamides; Animals; Circadian Rhythm; Disease Models, Animal; Hypnotics and Sedatives; Male; Melatonin; Rats; Sleep Wake Disorders | 1993 |
Thiazolidine diones, specific ligands of the nuclear receptor retinoid Z receptor/retinoid acid receptor-related orphan receptor alpha with potent antiarthritic activity.
Topics: Acetamides; Adjuvants, Immunologic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Autoimmune Diseases; Ligands; Male; Melatonin; Nuclear Receptor Subfamily 1, Group F, Member 1; Rats; Rats, Inbred Lew; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Receptors, Melatonin; Receptors, Retinoic Acid; Structure-Activity Relationship; Thiazoles; Thiosemicarbazones; Trans-Activators | 1996 |
Melatonin analogues as agonists and antagonists in the circadian system and other brain areas.
Topics: Acetamides; Animals; Circadian Rhythm; Cricetinae; Dose-Response Relationship, Drug; Electrophysiology; Hippocampus; Hypnotics and Sedatives; Iontophoresis; Male; Melatonin; Mesocricetus; Metergoline; Serotonin Antagonists; Suprachiasmatic Nucleus | 1996 |
Melatonin and its new agonist S-20098 restore synchronized sleep fragmented by experimental trypanosome infection in the rat.
Topics: Acetamides; Animals; Electroencephalography; Hypnotics and Sedatives; Male; Melatonin; Rats; Rats, Wistar; Sleep; Sleep Stages; Trypanosoma brucei brucei; Trypanosomiasis, African | 1996 |
Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent.
Topics: Acetamides; Animals; Circadian Rhythm; Dose-Response Relationship, Drug; Hypnotics and Sedatives; Male; Melatonin; Motor Activity; Rats | 1996 |
The antidopaminergic action of S-20098 is mediated by benzodiazepine/GABA(A) receptors in the striatum.
Topics: Acetamides; Animals; Bicuculline; Corpus Striatum; Dopamine Antagonists; Flumazenil; GABA Antagonists; GABA Modulators; Injections; Injections, Intraperitoneal; Male; Melatonin; Rats; Rats, Sprague-Dawley; Receptors, GABA-A | 1997 |
Comparative effects of a melatonin agonist on the circadian system in mice and Syrian hamsters.
Topics: Acetamides; Animals; Circadian Rhythm; Cricetinae; Dose-Response Relationship, Drug; Hypnotics and Sedatives; Injections, Intraperitoneal; Male; Melatonin; Mesocricetus; Mice; Mice, Inbred C3H; Species Specificity | 1997 |
Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intact suprachiasmatic nuclei but not the pineal.
Topics: Acetamides; Animals; Body Temperature; Circadian Rhythm; Male; Melatonin; Motor Activity; Pineal Gland; Rats; Rats, Inbred Strains; Suprachiasmatic Nucleus | 1998 |
Chronic exposure to melatonin receptor agonists does not alter their effects on suprachiasmatic nucleus neurons.
Topics: Acetamides; Animals; Circadian Rhythm; Cricetinae; Dose-Response Relationship, Drug; Electrophysiology; In Vitro Techniques; Male; Melatonin; Mesocricetus; Neurons; Photic Stimulation; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Receptors, Melatonin; Suprachiasmatic Nucleus | 1998 |
Resynchronisation of a diurnal rodent circadian clock accelerated by a melatonin agonist.
Topics: Acetamides; Animals; Circadian Rhythm; Darkness; Humans; Light; Male; Melatonin; Models, Biological; Muridae; Travel | 1998 |
Effects of two melatonin analogues, S-20098 and S-20928, on melatonin receptors in the pars tuberalis of the rat.
Topics: Acetamides; Animals; Autoradiography; Down-Regulation; Male; Melatonin; Naphthalenes; Pineal Gland; Rats; Rats, Wistar; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Receptors, Melatonin | 1998 |
Preclinical evaluation of the reinforcing and discriminative stimulus effects of agomelatine (S-20098), a melatonin agonist.
Topics: Acetamides; Animals; Conditioning, Operant; Discrimination, Psychological; Dose-Response Relationship, Drug; Hypnotics and Sedatives; Macaca mulatta; Male; Melatonin; Rats; Rats, Sprague-Dawley; Reward; Self Administration; Substance-Related Disorders | 1998 |
Involvement of nuclear binding sites for melatonin in the regulation of IL-2 and IL-6 production by human blood mononuclear cells.
Topics: Acetamides; Adult; Binding Sites; Cell Membrane; Cell Nucleus; Cytokines; Humans; Interleukin-2; Interleukin-6; Melatonin; Middle Aged; Monocytes; Thiazoles; Thiosemicarbazones | 1998 |
Vasoconstrictor effects of various melatonin analogs on the rat tail artery in the presence of phenylephrine.
Topics: Acetamides; Animals; Dose-Response Relationship, Drug; Drug Interactions; Endothelium; Male; Melatonin; Muscle, Smooth; Nerve Endings; Norepinephrine; Perfusion; Phenylephrine; Rats; Rats, Wistar; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Receptors, Melatonin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sympathetic Nervous System; Tail; Tryptamines; Vasoconstriction | 1999 |
Mechanisms of melatonin-induced vasoconstriction in the rat tail artery: a paradigm of weak vasoconstriction.
Topics: Acetamides; Animals; Anticonvulsants; Arteries; Calcium Channel Blockers; Charybdotoxin; Colforsin; Dose-Response Relationship, Drug; Hypnotics and Sedatives; In Vitro Techniques; Indoles; Male; Melatonin; Nifedipine; Nitroprusside; Potassium Channels; Rats; Rats, Sprague-Dawley; Tail; Tryptamines; Vasoconstriction; Vasoconstrictor Agents; Vasodilator Agents; Vasopressins | 1999 |
Organization of rat circadian rhythms during daily infusion of melatonin or S20098, a melatonin agonist.
Topics: Acetamides; Animals; Circadian Rhythm; Free Radical Scavengers; Hypnotics and Sedatives; Infusions, Intravenous; Male; Melatonin; Rats; Rats, Long-Evans | 1999 |
Determination of melatonin in biological fluids in the presence of the melatonin agonist S 20098: comparison of immunological techniques and GC-MS methods.
Topics: Acetamides; Antioxidants; Body Fluids; Chromatography, Liquid; Drug Stability; Gas Chromatography-Mass Spectrometry; Humans; Melatonin; Radioimmunoassay; Reference Standards; Reproducibility of Results; Saliva | 1999 |
Characterisation of human melatonin mt(1) and MT(2) receptors by CRE-luciferase reporter assay.
Topics: Acetamides; Amides; Animals; Cell Line; Cyclic AMP; Genes, Reporter; Humans; Iodine Radioisotopes; Kidney; Luciferases; Melatonin; Naphthalenes; Plasmids; Rats; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Receptors, Melatonin; Sheep; Transfection | 2000 |
Melatonin receptors in human uveal melanocytes and melanoma cells.
Topics: Acetamides; Blotting, Southern; Choroid Neoplasms; Dose-Response Relationship, Drug; Gene Expression; Humans; Melanocytes; Melanoma; Melatonin; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Receptors, Melatonin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Thiazoles; Thiosemicarbazones; Tumor Cells, Cultured | 2000 |
Stimulatory and entraining effect of melatonin on tuberoinfundibular dopaminergic neuron activity and inhibition on prolactin secretion.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetamides; Animals; Circadian Rhythm; Dose-Response Relationship, Drug; Female; Hypothalamus, Middle; Melatonin; Naphthalenes; Neurons; Ovariectomy; Prolactin; Rats; Rats, Sprague-Dawley; Time Factors | 2000 |
Photophysical studies on melatonin and its receptor agonists.
Topics: Acetamides; Hematoporphyrins; Kynurenine; Luminescent Measurements; Melatonin; Oxygen; Phenalenes; Photochemistry; Polycyclic Compounds; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Receptors, Melatonin; Spectrophotometry, Ultraviolet; Thiazoles; Thiosemicarbazones; Ultraviolet Rays | 2000 |
A melatonin agonist facilitates circadian resynchronization in old hamsters after abrupt shifts in the light-dark cycle.
Topics: Acetamides; Aging; Animals; Biological Clocks; Circadian Rhythm; Cricetinae; Darkness; Light; Melatonin; Photoperiod | 2000 |
Correlation between nuclear melatonin receptor expression and enhanced cytokine production in human lymphocytic and monocytic cell lines.
Topics: Acetamides; Adjuvants, Immunologic; Cell Membrane; Cell Nucleus; DNA Primers; Humans; Interleukin-2; Interleukin-6; Jurkat Cells; Lymphocytes; Melatonin; Monocytes; Phytohemagglutinins; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Receptors, Melatonin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetradecanoylphorbol Acetate; Thiazoles; Thiosemicarbazones; U937 Cells | 2000 |
Evidence of melatonin involvement in pindolol-induced suppression of REM sleep.
Topics: Acetamides; Adrenergic beta-Antagonists; Animals; Dose-Response Relationship, Drug; Male; Melatonin; Pindolol; Rats; Rats, Wistar; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Receptors, Melatonin; Sleep, REM | 2001 |
Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus.
Topics: Acetamides; Aging; Animals; Circadian Rhythm; Cricetinae; Darkness; Light; Male; Melatonin; Mesocricetus; Motor Activity; Photoperiod | 2001 |
Serine residues 110 and 114 are required for agonist binding but not antagonist binding to the melatonin MT(1) receptor.
Topics: Acetamides; Amides; Amino Acid Substitution; Animals; Binding Sites; Binding, Competitive; COS Cells; Cyclic AMP; Dose-Response Relationship, Drug; Heterotrimeric GTP-Binding Proteins; Humans; Indoles; Melatonin; Mutagenesis, Site-Directed; Naphthalenes; Protein Binding; Radioligand Assay; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Receptors, Melatonin; Recombinant Fusion Proteins; Serine; Structure-Activity Relationship; Transfection; Tryptamines | 2001 |
S20098 affects the free-running rhythms of body temperature and activity and decreases light-induced phase delays of circadian rhythms of the rat.
Topics: Acetamides; Animals; Body Temperature; Circadian Rhythm; Light; Male; Melatonin; Motor Activity; Rats; Rats, Wistar; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Receptors, Melatonin | 2001 |
Melatonin counteracts the inhibitory effect of PGE2 on IL-2 production in human lymphocytes via its mt1 membrane receptor.
Topics: Acetamides; Cyclic AMP; Dinoprostone; Gene Expression Regulation; Humans; Interleukin-2; Lymphocytes; Melatonin; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Receptors, Melatonin; RNA, Messenger; Tetradecanoylphorbol Acetate; Thiazoles; Thiosemicarbazones | 2003 |
Agomelatine(S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats.
Topics: Acetamides; Animals; Antidepressive Agents; Choroid Plexus; In Vitro Techniques; Indoles; Inositol Phosphates; Male; Melatonin; Naphthalenes; Penile Erection; Pizotyline; Pyridines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2C; Receptors, Melatonin; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Swine | 2003 |
Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade.
Topics: Acetamides; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Brain Chemistry; Clorazepate Dipotassium; Conflict, Psychological; Dose-Response Relationship, Drug; Hippocampus; Indoles; Interpersonal Relations; Male; Melatonin; Mice; Microdialysis; Motor Activity; Norepinephrine; Pyridines; Rats; Receptor, Serotonin, 5-HT2C; Receptors, GABA-A; Serotonin; Serotonin Antagonists; Synaptic Transmission; Thiophenes; Vocalization, Animal | 2005 |
RNA expression of human telomerase subunits TR and TERT is differentially affected by melatonin receptor agonists in the MCF-7 tumor cell line.
Topics: Acetamides; Breast Neoplasms; Catalytic Domain; Female; Humans; Hypnotics and Sedatives; Melatonin; Receptors, Melatonin; RNA; Signal Transduction; Telomerase; Thiazoles; Thiosemicarbazones; Tumor Cells, Cultured | 2004 |
Antidepressant-like effects of agomelatine, melatonin and the NK1 receptor antagonist GR205171 in impulsive-related behaviour in rats.
Topics: Acetamides; Animals; Antidepressive Agents; Appetitive Behavior; Conditioning, Operant; Impulsive Behavior; Male; Melatonin; Motivation; Neurokinin-1 Receptor Antagonists; Piperidines; Rats; Rats, Wistar; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Reinforcement Schedule; Tetrazoles; Thiophenes | 2005 |
Antidepressant action of agomelatine (S 20098) in a transgenic mouse model.
Topics: Acetamides; Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Behavior, Animal; Corticosterone; Depression; Desipramine; Disease Models, Animal; In Situ Hybridization; Male; Maze Learning; Melatonin; Mice; Mice, Transgenic; Receptors, Glucocorticoid; Swimming; Telemetry; Time Factors | 2005 |
Effects of melatonin and agomelatine in anxiety-related procedures in rats: interaction with diazepam.
Topics: Acetamides; Animals; Anxiety; Conditioning, Operant; Diazepam; Dose-Response Relationship, Drug; Drug Interactions; Male; Melatonin; Motor Activity; Rats; Rats, Wistar | 2006 |
Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety.
Topics: Acetamides; Animals; Anti-Anxiety Agents; Arousal; Brain; Buspirone; Chronotherapy; Conditioning, Classical; Diazepam; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Electroshock; Exploratory Behavior; Fear; Male; Maze Learning; Melatonin; Rats; Receptor, Serotonin, 5-HT2C; Receptors, Melatonin; Thiophenes; Vocalization, Animal | 2006 |
Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model.
Topics: Acetamides; Aminopyridines; Animals; Antidepressive Agents; Avoidance Learning; Helplessness, Learned; Imipramine; Indoles; Male; Melatonin; Rats; Rats, Wistar; Receptors, Melatonin; Serotonin 5-HT2 Receptor Antagonists; Thiophenes | 2006 |
First evidence of melatonin receptors distribution in the suprachiasmatic nucleus of tree shrew brain.
Topics: Acetamides; Animals; Autoradiography; Binding Sites; Brain; Circadian Rhythm; Female; Melatonin; Memory; Receptors, Melatonin; Stress, Psychological; Suprachiasmatic Nucleus; Tupaiidae | 2007 |
Agomelatine, a melatonin receptor agonist with 5-HT(2C) receptor antagonist properties, protects the developing murine white matter against excitotoxicity.
Topics: Acetamides; Animals; Brain; Brain Diseases; Excitatory Amino Acid Agonists; Ibotenic Acid; Melatonin; Mice; Neuroprotective Agents; Receptor, Serotonin, 5-HT2C; Receptors, Melatonin; Serotonin Antagonists; Tryptamines | 2008 |
Melatonin and its agonists: an update.
Topics: Acetamides; Benzofurans; Cyclopropanes; Drug Administration Schedule; Humans; Indenes; Melatonin; Receptors, Melatonin | 2008 |
Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture.
Topics: Acetamides; Analysis of Variance; Animals; Behavior, Animal; Central Nervous System Depressants; Circadian Rhythm; Hypnotics and Sedatives; Indenes; Indoles; Melatonin; Pyridines; Rats; Rats, Wistar; Serotonin Antagonists; Sleep; Wakefulness | 2009 |
Agomelatine: new drug. Adverse effects and no proven efficacy.
Topics: Acetamides; Animals; Antidepressive Agents; Bias; Carcinogens; Clinical Trials as Topic; Cyclohexanols; Depression; Depressive Disorder; Double-Blind Method; Drug Approval; Europe; Fluoxetine; Humans; Hypnotics and Sedatives; Melatonin; Paroxetine; Psychiatric Status Rating Scales; Receptors, Melatonin; Recurrence; Selective Serotonin Reuptake Inhibitors; Suicide; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration.
Topics: Acetamides; Animals; Brain-Derived Neurotrophic Factor; Gene Expression; Hippocampus; Hypnotics and Sedatives; Indoles; Male; Melatonin; Prefrontal Cortex; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Melatonin; Receptors, Serotonin, 5-HT2; RNA, Messenger; Serotonin Antagonists; Up-Regulation | 2010 |
[Clinical experiences with agomelatine. The inner ear has to be synchronized again].
Topics: Acetamides; Antidepressive Agents; Circadian Rhythm; Controlled Clinical Trials as Topic; Depression; Ear, Inner; Humans; Hypnotics and Sedatives; Melatonin; Nervous System Diseases; Selective Serotonin Reuptake Inhibitors; Sertraline; Sleep Wake Disorders; Tranquilizing Agents | 2010 |
Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways.
Topics: Acetamides; Analysis of Variance; Animals; Central Nervous System Depressants; Electroshock; Frontal Lobe; gamma-Aminobutyric Acid; Glutamic Acid; Indoles; Melatonin; Pyridines; Rats; Receptor, Serotonin, 5-HT2C; Receptors, Melatonin; Stress, Physiological; Synaptosomes | 2010 |
Effect of agomelatine and its interaction with the daily corticosterone rhythm on progenitor cell proliferation in the dentate gyrus of the adult rat.
Topics: Acetamides; Analysis of Variance; Animals; Cell Proliferation; Circadian Rhythm; Corticosterone; Dentate Gyrus; Immunohistochemistry; Male; Melatonin; Neural Stem Cells; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2C | 2010 |
Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat.
Topics: Acetamides; Aminopyridines; Animals; Antidepressive Agents; Drug Chronotherapy; Indoles; Male; Melatonin; Memory; Rats; Rats, Sprague-Dawley; Recognition, Psychology; Serotonin; Serotonin 5-HT2 Receptor Antagonists | 2011 |
The depression market.
Topics: Acetamides; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder; Drug Discovery; Humans; Melatonin | 2011 |
Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: a comparison to melatonin and to the 5-HT(2c) antagonist, S32006.
Topics: Acetamides; Animals; Antidepressive Agents; Behavior, Animal; Hyperkinesis; Indoles; Male; Melatonin; Olfactory Bulb; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Antagonists | 2012 |
The influence of melatonin and agomelatine on urodynamic parameters in experimental overactive bladder model--preliminary results.
Topics: Acetamides; Animals; Case-Control Studies; Central Nervous System Depressants; Disease Models, Animal; Female; Hypnotics and Sedatives; Melatonin; Random Allocation; Rats; Rats, Wistar; Urinary Bladder, Overactive; Urodynamics | 2011 |
Anticonvulsant effects of agomelatine in mice.
Topics: Acetamides; Animals; Anticonvulsants; Convulsants; Dose-Response Relationship, Drug; Female; Melatonin; Mice; Seizures; Time Factors | 2012 |
Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine, and serotonin systems in the rat brain.
Topics: Acetamides; Action Potentials; Animals; Brain; Dopamine; Electrophysiological Phenomena; Male; Melatonin; Norepinephrine; Rats; Rats, Sprague-Dawley; Receptors, Melatonin; Serotonin; Thiophenes | 2013 |
Melatonin analogue agomelatine reduces rabbit's intraocular pressure in normotensive and hypertensive conditions.
Topics: Acetamides; Animals; Dose-Response Relationship, Drug; Intraocular Pressure; Melatonin; Ocular Hypertension; Rabbits | 2013 |
Agomelatine, melatonin and depressive disorder.
Topics: Acetamides; Animals; Antidepressive Agents; Circadian Rhythm; Depression; Depressive Disorder; Humans; Melatonin | 2013 |
[The combined therapy with valdoxan and amitriptyline of treatment resistant somatized depression].
Topics: Acetamides; Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Circadian Rhythm; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hypnotics and Sedatives; Male; Melatonin; Middle Aged; Sleep; Treatment Outcome | 2013 |
Agomelatine in the tree shrew model of depression: effects on stress-induced nocturnal hyperthermia and hormonal status.
Topics: Acetamides; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Body Temperature; Body Weight; Central Nervous System Depressants; Circadian Rhythm; Depressive Disorder; Fever; Fluoxetine; Hydrocortisone; Indoles; Male; Melatonin; Motor Activity; Norepinephrine; Pyridines; Serotonin 5-HT2 Receptor Antagonists; Stress, Psychological; Tupaiidae | 2014 |
Therapeutic potential of agomelatine in epilepsy and epileptic complications.
Topics: Acetamides; Antidepressive Agents; Cell Survival; Circadian Rhythm; Drug Discovery; Epilepsy; Hippocampus; Humans; Melatonin; Models, Biological; Neurogenesis; Receptors, Melatonin; Receptors, Serotonin | 2014 |
Like melatonin, agomelatine (S20098) increases the amplitude of oscillations of two clock outputs: melatonin and temperature rhythms.
Topics: Acetamides; Animals; Circadian Rhythm; Male; Melatonin; Photoperiod; Rats; Rats, Wistar; Serotonin; Suprachiasmatic Nucleus; Temperature | 2014 |
Challenging behaviour and sleep cycle disorder following brain injury: a preliminary response to agomelatine treatment.
Topics: Acetamides; Brain Injuries; Cognition Disorders; Humans; Hypnotics and Sedatives; Male; Melatonin; Mental Disorders; Middle Aged; Quality of Life; Sleep Disorders, Circadian Rhythm; Time Factors; Treatment Outcome | 2014 |
[Effects of melaxen and valdoxan on the activity of glutathione antioxidant system and NADPH-producing enzymes in rat heart under experimental hyperthyroidism conditions].
Topics: Acetamides; Animals; Antioxidants; Glucosephosphate Dehydrogenase; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Heart; Hyperthyroidism; Isocitrate Dehydrogenase; Male; Melatonin; NADP; Rats; Reactive Oxygen Species; Triiodothyronine | 2013 |
Multi-matrix assay of the first melatonergic antidepressant agomelatine by combined liquid chromatography-fluorimetric detection and microextraction by packed sorbent.
Topics: Acetamides; Antidepressive Agents; Chromatography, High Pressure Liquid; Drug Stability; Female; Fluorometry; Humans; Male; Melatonin; Middle Aged; Solid Phase Microextraction | 2014 |
Agomelatine-associated manic switch in bipolar depression: a case report.
Topics: Acetamides; Adult; Antidepressive Agents; Bipolar Disorder; Female; Humans; Melatonin | 2014 |
[The use of agomelatine for the preventive treatment of migraine].
Topics: Acetamides; Adult; Female; Humans; Hypnotics and Sedatives; Melatonin; Middle Aged; Migraine Disorders; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Treatment Outcome | 2014 |
Pharmacological benefits of agomelatine and vanillin in experimental model of Huntington's disease.
Topics: Acetamides; Animals; Benzaldehydes; Disease Models, Animal; Female; Huntington Disease; Male; Maze Learning; Melatonin; Motor Activity; Nitro Compounds; Propionates; Rats; Rats, Wistar; TRPV Cation Channels | 2014 |
[Investigation into the vestibular protective properties of melatoninergic agents].
Topics: Acetamides; Animals; Animals, Newborn; Animals, Outbred Strains; Bicuculline; Central Nervous System Depressants; Excitatory Postsynaptic Potentials; GABA-A Receptor Antagonists; Male; Medulla Oblongata; Melatonin; Neurons; Patch-Clamp Techniques; Rats; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Tryptamines; Vestibule, Labyrinth | 2014 |
[Problems of depressive insomnia].
Topics: Acetamides; Adult; Circadian Rhythm; Depressive Disorder, Major; Female; Humans; Hypnotics and Sedatives; Male; Melatonin; Middle Aged; Psychiatric Status Rating Scales; Sleep Initiation and Maintenance Disorders; Treatment Outcome | 2014 |
Oral treatment with the melatonin agonist agomelatine lowers the intraocular pressure of glaucoma patients.
Topics: Acetamides; Administration, Oral; Aged; Antihypertensive Agents; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Melatonin; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Pilot Projects; Prospective Studies | 2015 |
Convergence of melatonin and serotonin (5-HT) signaling at MT2/5-HT2C receptor heteromers.
Topics: Acetamides; Arrestins; beta-Arrestins; Drug Synergism; Gene Expression Regulation; HEK293 Cells; HeLa Cells; Humans; Melatonin; Protein Multimerization; Protein Structure, Quaternary; Protein Transport; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Receptor, Serotonin, 5-HT2C; Serotonin; Signal Transduction; Transcriptional Activation; Type C Phospholipases | 2015 |
[A new approach to the search for vestibuloprotectors].
Topics: Acetamides; Animals; Drug Design; Glutamic Acid; Humans; Melatonin; Motion Sickness; Picolines; Promethazine; Rats; Receptors, GABA-A; Receptors, Melatonin; Scopolamine | 2015 |
Activation of Melatonin Receptors Reduces Relapse-Like Alcohol Consumption.
Topics: Acetamides; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Aminopyridines; Animals; Choice Behavior; Circadian Rhythm; Disease Models, Animal; Indoles; Male; Melatonin; Motor Activity; Rats, Wistar; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists | 2015 |
[An effect of valdoxan on the hemostasis in patients with acute coronary syndrome in the combination with anxiety and depressive disorders].
Topics: Acetamides; Acute Coronary Syndrome; Adult; Aged; Anxiety; Central Nervous System Depressants; Depressive Disorder; Dose-Response Relationship, Drug; Female; Hemostasis; Humans; Male; Melatonin; Middle Aged; Treatment Outcome | 2015 |
Does melatonin treatment change emotional processing? Implications for understanding the antidepressant mechanism of agomelatine.
Topics: Acetamides; Adolescent; Adult; Antidepressive Agents; Circadian Rhythm; Double-Blind Method; Emotions; Female; Healthy Volunteers; Humans; Male; Melatonin; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Antagonists; Young Adult | 2015 |
Agomelatine Protection in an LPS-Induced Psychosis-Relevant Behavior Model.
Topics: Acetamides; Animals; Brain; Lipopolysaccharides; Male; Malondialdehyde; Melatonin; Psychotic Disorders; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha | 2015 |
Agomelatine Improves Apathy in Frontotemporal Dementia.
Topics: Acetamides; Antidepressive Agents; Apathy; Double-Blind Method; Female; Frontotemporal Dementia; Humans; Male; Melatonin; Middle Aged; Psychiatric Status Rating Scales; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome | 2016 |
Mouse psychosocial stress reduces motivation and cognitive function in operant reward tests: A model for reward pathology with effects of agomelatine.
Topics: Acetamides; Animals; Antidepressive Agents; Automation, Laboratory; Circadian Rhythm; Conditioning, Operant; Dietary Sucrose; Dominance-Subordination; Feeding Behavior; Indoles; Male; Melatonin; Mice, Inbred C57BL; Models, Animal; Motivation; Pyridines; Receptor, Serotonin, 5-HT2C; Reversal Learning; Reward; Saccharin; Serotonin Antagonists; Stress, Psychological | 2016 |
Agomelatine and Transient Elevation of Creatine Phosphokinase.
Topics: Acetamides; Adult; Antidepressive Agents; Creatine Kinase; Depression; Humans; Liver; Liver Function Tests; Male; Melatonin; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2 | 2016 |
The effect of agomelatine and melatonin on sleep-related eating: a case report.
Topics: Acetamides; Central Nervous System Depressants; Depressive Disorder, Major; Female; Humans; Melatonin; Middle Aged; Night Eating Syndrome; Panic Disorder; Patient Compliance; Sleep Wake Disorders; Treatment Outcome; Weight Gain | 2017 |
Maternal melatonin or agomelatine therapy prevents programmed hypertension in male offspring of mother exposed to continuous light.
Topics: Acetamides; Animals; Antioxidants; Female; Hypertension; Hypnotics and Sedatives; Light; Male; Maternal Exposure; Melatonin; Pregnancy; Prenatal Exposure Delayed Effects; Proto-Oncogene Mas; Rats; Rats, Sprague-Dawley | 2017 |
Disturbances of diurnal phase markers, behavior, and clock genes in a rat model of depression; modulatory effects of agomelatine treatment.
Topics: Acetamides; Animals; Antidepressive Agents; Circadian Rhythm; CLOCK Proteins; Depression; Disease Models, Animal; Male; Melatonin; Period Circadian Proteins; Rats; Rats, Wistar; Treatment Outcome | 2018 |
Agomelatine, a novel therapeutic option for the management of irritable bowel syndrome.
Topics: Acetamides; Adolescent; Adult; Aged; Female; Humans; Hypnotics and Sedatives; Irritable Bowel Syndrome; Male; Melatonin; Middle Aged; Receptors, Serotonin; Young Adult | 2018 |
Antidepressant agomelatine attenuates behavioral deficits and concomitant pathology observed in streptozotocin-induced model of Alzheimer's disease in male rats.
Topics: Acetamides; Alzheimer Disease; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Disease Models, Animal; Exploratory Behavior; Hippocampus; Male; Maze Learning; Melatonin; Memory Disorders; Rats; Rats, Sprague-Dawley; Streptozocin | 2019 |
Structural basis of ligand recognition at the human MT
Topics: Acetamides; Amino Acid Sequence; Antidepressive Agents; Crystallization; Electrons; Humans; Indenes; Lasers; Ligands; Melatonin; Models, Molecular; Molecular Docking Simulation; Mutation; Receptor, Melatonin, MT1; Receptor, Serotonin, 5-HT2C; Structure-Activity Relationship; Substrate Specificity | 2019 |
Cardioprotective effect of melatonin and agomelatine on doxorubicin-induced cardiotoxicity in a rat model: an electrocardiographic, scintigraphic and biochemical study.
Topics: Acetamides; Animals; Antibiotics, Antineoplastic; Antioxidants; Cardiotoxicity; Doxorubicin; Electrocardiography; Heart; Male; Melatonin; Myocardium; Radionuclide Imaging; Rats; Rats, Wistar | 2019 |
Inhibition of autophagy triggers melatonin-induced apoptosis in glioblastoma cells.
Topics: Acetamides; Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Glioblastoma; Humans; Macrolides; Melatonin; Receptors, Melatonin; Tryptamines | 2019 |
Agomelatine protects against permanent cerebral ischaemia via the Nrf2-HO-1 pathway.
Topics: Acetamides; Animals; Brain; Heme Oxygenase (Decyclizing); Infarction, Middle Cerebral Artery; Male; Melatonin; Neurons; Neuroprotective Agents; NF-E2-Related Factor 2; Rats, Wistar; Signal Transduction | 2020 |
Do peripheral melatonin agonists improve bone fracture healing? The effects of agomelatine and ramelteon on experimental bone fracture.
Topics: Acetamides; Animals; Femoral Fractures; Fracture Healing; Fractures, Bone; Indenes; Male; Melatonin; Osteogenesis; Polymerase Chain Reaction; Rats; Rats, Wistar; RNA, Messenger; X-Rays | 2020 |
A Topical Formulation of Melatoninergic Compounds Exerts Strong Hypotensive and Neuroprotective Effects in a Rat Model of Hypertensive Glaucoma.
Topics: Acetamides; Animals; Antihypertensive Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Disease Models, Animal; Glaucoma; Gliosis; Melatonin; Neuroprotective Agents; Rats; Retina; Signal Transduction; Treatment Outcome | 2020 |
Increased spindle density correlates with sleep continuity improvements following an eight-week course of a melatonin agonist in people with depression: A proof-of-concept study with agomelatine.
Topics: Acetamides; Adolescent; Adult; Depression; Humans; Melatonin; Sleep; Young Adult | 2021 |
Agomelatine reduces circulating triacylglycerides and hepatic steatosis in fructose-treated rats.
Topics: Acetamides; Animals; Apolipoproteins B; Body Weight; Carrier Proteins; Energy Intake; Fatty Liver; Fructose; Hypertriglyceridemia; Hypolipidemic Agents; Lipid Metabolism; Lipoproteins, VLDL; Liver; Male; Melatonin; Olive Oil; Rats; Rats, Wistar; Receptors, Melatonin; Triglycerides | 2021 |
Therapeutic potential of melatonin and melatonergic drugs on K18-hACE2 mice infected with SARS-CoV-2.
Topics: Acetamides; Animals; COVID-19; COVID-19 Drug Treatment; Indenes; Lung; Melatonin; Mice; Mice, Inbred C57BL; Mice, Transgenic; SARS-CoV-2; Viral Load | 2022 |
Agomelatine: An Astounding Sui-generis Antidepressant?
Topics: Acetamides; Antidepressive Agents; Depressive Disorder, Major; Humans; Melatonin; Naphthalenes; Receptors, Melatonin | 2022 |
Agomelatine, a structural analog of melatonin, improves kidney dysfunction through regulating the AMPK/mTOR signaling pathway to promote autophagy in obese rats.
Topics: Acetamides; AMP-Activated Protein Kinases; Animals; Autophagy; Insulin Resistance; Kidney; Male; Melatonin; Naphthalenes; Obesity; Rats; Rats, Wistar; Signal Transduction; TOR Serine-Threonine Kinases | 2022 |
The melatonergic agonist agomelatine ameliorates high fat diet-induced obesity in mice through the modulation of the gut microbiome.
Topics: Acetamides; Animals; Diet, High-Fat; Dysbiosis; Gastrointestinal Microbiome; Humans; Male; Melatonin; Mice; Mice, Inbred C57BL; Naphthalenes; Obesity | 2022 |